Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab monotherapy within its marketing authorisation for untreated advanced non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 1678

Provisional Schedule

Committee meeting: 1 11 March 2021
Expected publication 02 June 2021

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors Roche (atezolizumab)
Others Department of Health and Social care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Actavis UK (gemcitabine, paclitaxel, pemetrexed, vinorelbine) (confidentiality agreement not signed, not participating)
  Celgene (paclitaxel) (confidentiality agreement not signed, not participating)
  Dr. Reddy’s Laboratories (pemetrexed) (confidentiality agreement not signed, not participating)
  Eli Lilly (gemcitabine, pemetrexed) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  medac (docetaxel, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Merck Sharp & Dohme (pembrolizumab) (confidentiality agreement not signed, not participating)
  Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  Roche (atezolizumab, bevacizumab, erlotinib) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
  Sanofi (docetaxel)
  Seacross Pharmaceuticals (docetaxel, pemetrexed) (confidentiality agreement not signed, not participating)
  Sun Pharma (gemcitabine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
11 June 2020 Please note that following on from communications with the company, the timelines for this appraisal have now been updated. The new committee date will be Thursday 11 March 2021.
03 April 2020 Invitation to participate
07 January 2020 - 04 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance